Literature DB >> 16462760

Identification of RASSF8 as a candidate lung tumor suppressor gene.

F S Falvella1, G Manenti, M Spinola, C Pignatiello, B Conti, U Pastorino, T A Dragani.   

Abstract

The RASSF8 gene, which maps close to the KRAS2 gene, contains a RAS-associated domain and encodes a protein that is evolutionarily conserved from fish to humans. Analysis of the RASSF8 transcript revealed a complex expression pattern of 5'-UTR mRNA isoforms in normal lung and in lung adenocarcinomas (ADCAs), with no apparent differences. However, RASSF8 gene transcript levels were approximately seven-fold-lower in lung ADCAs as compared to normal lung tissue. Expression of RASSF8 protein by transfected lung cancer cells led to inhibition of anchorage-independent growth in soft agar in A549 cells and reduction of clonogenic activity in NCI-H520 cells. These results raise the possibility protein encoded by RASSF8 is a novel tumor suppressor for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462760     DOI: 10.1038/sj.onc.1209422

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Long-term effects of carbon containing engineered nanomaterials and asbestos in the lung: one year postexposure comparisons.

Authors:  Anna A Shvedova; Naveena Yanamala; Elena R Kisin; Alexey V Tkach; Ashley R Murray; Ann Hubbs; Madalina M Chirila; Phouthone Keohavong; Lyudmila P Sycheva; Valerian E Kagan; Vincent Castranova
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

2.  E4BP4/NFIL3 modulates the epigenetically repressed RAS effector RASSF8 function through histone methyltransferases.

Authors:  Isai Pratha Karthik; Pavitra Desai; Sudarkodi Sukumar; Aleksandra Dimitrijevic; Krishnaraj Rajalingam; Sundarasamy Mahalingam
Journal:  J Biol Chem       Date:  2018-02-21       Impact factor: 5.157

3.  Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis.

Authors:  Asha Recino; Victoria Sherwood; Amy Flaxman; Wendy N Cooper; Farida Latif; Andrew Ward; Andrew D Chalmers
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

4.  RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis.

Authors:  Victoria Sherwood; Ria Manbodh; Carol Sheppard; Andrew D Chalmers
Journal:  Mol Biol Cell       Date:  2008-02-13       Impact factor: 4.138

Review 5.  N-terminal RASSF family: RASSF7-RASSF10.

Authors:  Nicholas Underhill-Day; Victoria Hill; Farida Latif
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

6.  The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Authors:  Anna Djos; Tommy Martinsson; Per Kogner; Helena Carén
Journal:  Mol Cancer       Date:  2012-06-13       Impact factor: 27.401

7.  Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy.

Authors:  Jennifer Clark; Jessica Freeman; Howard Donninger
Journal:  Mol Biol Int       Date:  2012-05-24

8.  Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer.

Authors:  Reo Maruyama; Kimishige Akino; Minoru Toyota; Hiromu Suzuki; Takashi Imai; Mutsumi Ohe-Toyota; Eiichiro Yamamoto; Masanori Nojima; Tomoko Fujikane; Yasushi Sasaki; Toshiharu Yamashita; Yoshiyuki Watanabe; Hiroyoshi Hiratsuka; Koichi Hirata; Fumio Itoh; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  Carcinogenesis       Date:  2008-02-29       Impact factor: 4.944

Review 9.  The Ras-association domain family (RASSF) members and their role in human tumourigenesis.

Authors:  Louise van der Weyden; David J Adams
Journal:  Biochim Biophys Acta       Date:  2007-07-04

10.  Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features.

Authors:  K Harada; S Hiraoka; J Kato; J Horii; H Fujita; K Sakaguchi; Y Shiratori
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.